NAICS 325414: Biological Product
This U.S. industry comprises establishments primarily engaged in manufacturing vaccines, toxoids, blood fractions, and culture media of plant or animal origin (except diagnostic).

ExioML sector: Chemicals nec
Region: US | Year: 2022
Sector value added: 183879.917188 M EUR | Employment: 2033.54236812 thousand persons
Sector GHG emissions: 125728834468.0 kg CO2 eq | Energy carrier net total: 3186425.50957 TJ | Carbon intensity: 0.6837551179635024

Company: Grifols Therapeutics LLC
Grifols is a leading global healthcare company. Our trusted and innovative plasma-derived medicines, other biopharmaceuticals and solutions in transfusion medicine enable millions of patients around the world to lead more productive lives.